Lotus Neuro
Lotus Neuro is a clinical-stage therapeutics innovator developing a programmable, non-invasive focused ultrasound platform that enables targeted, real-time delivery across the blood-brain barrier anywhere in the brain. The modality-agnostic system works with small molecules, biologics, oligos, gene, and cell therapies without requiring drug redesign, starting with neuro-oncology applications. The platform is designed to help biopharmaceutical partners generate clinical evidence for CNS therapies previously limited by delivery challenges.
- Healthcare Technology
- Medical Devices
- Hardware
Funding
Funding not disclosed
Founders
Founder details are not available yet.
Product
Problem
The brain is one of the most difficult organs to treat, as many promising therapeutics struggle to cross the blood-brain barrier with the precision and consistency needed for effective outcomes. Even as breakthrough therapies emerge, delivery limitations often constrain their potential, leaving patients without access to treatments that could otherwise help them.
Solution
Lotus Neuro is building a programmable, non-invasive focused ultrasound platform designed to enable measurable and controllable therapeutic effects in the brain. The technology delivers non-invasive, targeted access across the blood-brain barrier anywhere in the brain, with real-time and repeatable delivery capabilities. Starting in neuro-oncology, the platform is modality-agnostic, compatible with small molecules, biologics, oligos, gene, and cell therapies without requiring drug redesign. The company aims to help partners generate clinical evidence and unlock the potential of therapies limited by delivery, bridging the gap between innovation and patient impact.
Target Audience
Primary customers are biopharmaceutical partners developing CNS therapies that face blood-brain barrier delivery challenges, particularly those with neuro-oncology programs seeking clinical evidence generation.
Features
- Non-invasive, targeted focused ultrasound for blood-brain barrier opening with real-time, repeatable delivery anywhere in the brain
- Programmable therapeutic window enabling precision control over delivery parameters
- Modality-agnostic platform compatible with small molecules, biologics, oligos, gene, and cell therapies
- No requirement for drug redesign when using the platform
- Clinical-stage development starting in neuro-oncology with planned expansion across modalities and neurological diseases